Get startedLog in
    Picture of ORYZON Genomics SA logo

    ORY — ORYZON Genomics SA News Story

    0.000.00%
    es flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapSucker Stock
    All News

    Brief: Oryzon Announces First Patient Dosed In Nci-Sponsored Phase I/Ii Clinical Trial Of Iadademstat Plus Immune Checkpoint Inhibitors In 1L Extensive Stage Small Cell Lung Cancer

    Picture of ORYZON Genomics SA logoORYZON Genomics SA
    15/04/2025 14:22
    April 15 (Reuters) - Oryzon Genomics SA ORY.MC:

ORYZON ANNOUNCES FIRST PATIENT DOSED IN NCI-SPONSORED PHASE I/II CLINICAL TRIAL OF IADADEMSTAT PLUS IMMUNE CHECKPOINT INHIBITORS IN 1L EXTENSIVE STAGE SMALL CELL LUNG CANCER

Source text: ID:nGNX8nS7rj

Further company coverage: ORY.MC

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on ORYZON Genomics SA

    See all news